Shopping Cart 0
Cart Subtotal
USD 0

BELLUS Health Inc (BLU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company's pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second indication called sarcoidosis; AMO-01 related to Fragile X syndrome and ALZ-801 for the treatment of Alzheimer's disease. BELLUS Health is headquartered in Laval, Quebec, Canada.

BELLUS Health Inc (BLU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

Asclepios Bioresearch To Invest In Bellus Health 10

Licensing Agreements 11

BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11

Bellus Health Enters into Licensing Agreement with AMO Pharma 12

Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13

Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14

Equity Offering 15

BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15

Acquisition 17

Taro Pharma To Acquire Thallion Pharma for USD2 Million 17

Bellus Health Completes Acquisition Of Thallion Pharma For USD 6.3 Million 18

Pharmascience Acquires 10.4% Stake In Bellus Health For USD 17.4 Million 19

BELLUS Health Inc-Key Competitors 21

BELLUS Health Inc-Key Employees 22

BELLUS Health Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 08, 2018: BELLUS Health reports financial and operating results for the second quarter ended june 30, 2018 24

May 15, 2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018 26

Feb 21, 2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017 28

Nov 08, 2017: BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017 30

Aug 09, 2017: BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017 31

Feb 28, 2017: Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016 33

Corporate Communications 35

Sep 27, 2017: BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

BELLUS Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Asclepios Bioresearch To Invest In Bellus Health 10

BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11

Bellus Health Enters into Licensing Agreement with AMO Pharma 12

Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13

Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14

BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15

Taro Pharma To Acquire Thallion Pharma for USD2 Million 17

Bellus Health Completes Acquisition Of Thallion Pharma For USD 6.3 Million 18

Pharmascience Acquires 10.4% Stake In Bellus Health For USD 17.4 Million 19

BELLUS Health Inc, Key Competitors 21

BELLUS Health Inc, Key Employees 22

BELLUS Health Inc, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BELLUS Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company's pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second indication called sarcoidosis; AMO-01 related to Fragile X syndrome and ALZ-801 for the treatment of Alzheimer's disease. BELLUS Health is headquartered in Laval, Quebec, Canada.

BELLUS Health Inc (BLU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

Asclepios Bioresearch To Invest In Bellus Health 10

Licensing Agreements 11

BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11

Bellus Health Enters into Licensing Agreement with AMO Pharma 12

Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13

Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14

Equity Offering 15

BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15

Acquisition 17

Taro Pharma To Acquire Thallion Pharma for USD2 Million 17

Bellus Health Completes Acquisition Of Thallion Pharma For USD 6.3 Million 18

Pharmascience Acquires 10.4% Stake In Bellus Health For USD 17.4 Million 19

BELLUS Health Inc-Key Competitors 21

BELLUS Health Inc-Key Employees 22

BELLUS Health Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 08, 2018: BELLUS Health reports financial and operating results for the second quarter ended june 30, 2018 24

May 15, 2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018 26

Feb 21, 2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017 28

Nov 08, 2017: BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017 30

Aug 09, 2017: BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017 31

Feb 28, 2017: Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016 33

Corporate Communications 35

Sep 27, 2017: BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

BELLUS Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BELLUS Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Asclepios Bioresearch To Invest In Bellus Health 10

BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11

Bellus Health Enters into Licensing Agreement with AMO Pharma 12

Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13

Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14

BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15

Taro Pharma To Acquire Thallion Pharma for USD2 Million 17

Bellus Health Completes Acquisition Of Thallion Pharma For USD 6.3 Million 18

Pharmascience Acquires 10.4% Stake In Bellus Health For USD 17.4 Million 19

BELLUS Health Inc, Key Competitors 21

BELLUS Health Inc, Key Employees 22

BELLUS Health Inc, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BELLUS Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.